Make the switch from IR to MOTPOLY XR

chart

MOTPOLY XR may be taken with or without food¹
MOTPOLY XR capsules should be swallowed whole with liquid. Patients should not open, chew, or crush the capsules¹

pills

MOTPOLY XR comes as a 100‑mg, 150‑mg, and 200‑mg capsule

*VIMPAT is a registered trademark used under license from Harris FRC Corporation. All other trademarks are the property of their respective owners.

MOTPOLY XR provides dosing convenience for new patients

Chart

chart

For patients who are already on a single AED and will convert to MOTPOLY XR monotherapy, withdrawal of the concomitant AED should not occur until the therapeutic dosage of MOTPOLY XR is achieved and has been administered for at least 4 days. A gradual withdrawal of the concomitant AED over at least 6 weeks is recommended¹
MOTPOLY XR may be taken with or without food¹
MOTPOLY XR capsules should be swallowed whole with liquid. Patients should not open, chew, or crush the capsules¹

pills

MOTPOLY XR comes as a 100‑mg, 150‑mg, and 200‑mg capsule

* When not specified, the dosage is the same for monotherapy for partial-onset seizures and adjunctive therapy for partial-onset seizures or primary generalized tonic‑clonic seizures.

^† Monotherapy for partial-onset seizures only.

AED=anti-epileptic drug.

INDICATION

MOTPOLY XR is indicated for adults and pediatric patients weighing at least 50 kg for treatment of partial-onset seizures and adjunctive therapy in the treatment of primary generalized tonic‑clonic seizures.

IMPORTANT SAFETY INFORMATION

WARNINGS AND PRECAUTIONS

Antiepileptic drugs increase the risk of suicidal behavior and ideation. Monitor patients for the emergence or worsening of depression, suicidal thoughts or behaviors.

INDICATION

MOTPOLY XR is indicated for adults and pediatric patients weighing at least 50 kg for treatment of partial-onset seizures and adjunctive therapy in the treatment of primary generalized tonic‑clonic seizures.

IMPORTANT SAFETY INFORMATION

WARNINGS AND PRECAUTIONS

Antiepileptic drugs increase the risk of suicidal behavior and ideation. Monitor patients for the emergence or worsening of depression, suicidal thoughts or behaviors.
MOTPOLY XR may cause dizziness and ataxia in patients. Advise patients not to operate machinery or motor vehicles until they know how MOTPOLY XR affects them.
Obtain ECG before beginning MOTPOLY XR, and after titration to steady-state maintenance dose in patients with underlying proarrhythmic conditions or on concomitant medications that affect cardiac conduction. Closely monitor these patients.
MOTPOLY XR may cause syncope.
Gradually withdraw MOTPOLY XR to minimize the potential of increased seizure frequency.
Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS)/multi-organ hypersensitivity has been reported and can be life-threatening or fatal. If signs or symptoms are present, immediately evaluate the patient. Discontinue MOTPOLY XR if there is no alternative etiology.

MOST COMMON ADVERSE REACTIONS

The most common adverse reactions in adults (≥10% and greater than placebo) are diplopia, headache, dizziness, nausea, and somnolence.

USE IN SPECIFIC POPULATIONS:

Dose adjustment is recommended for severe renal impairment and mild or moderate hepatic impairment. Consider dose reduction in patients with renal or hepatic impairment taking strong inhibitors of CYP3A4 and CYP2C9.
Use is not recommended in severe hepatic impairment.
Based on animal data, MOTPOLY XR may cause fetal harm if used in pregnancy.

Please refer to the full Prescribing Information and Medication Guide for MOTPOLY XR for additional important information.

References:
1. MOTPOLY XR [package insert]. Piscataway, NJ: Aucta Pharmaceuticals, Inc.; 2024. 2. Vimpat [package insert]. Smyrna, GA: UCB, Inc.; 2021.